

ONLINE FILING

Date: August 11, 2022

The Secretary, National Stock Exchange of India Ltd. Exchange Plaza, Bandra-Kurla Complex, Bandra (E), Mumbai-400051 NSE Code: ARTEMISMED	The Secretary, BSE Ltd Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai-400 001 Scrip Code: 542919
--	--

Sub: Outcome of Board Meeting held on August 11, 2022

Dear Sir/Ma'am,

Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, ("Listing Regulations, 2015") we wish to inform you that the Board of Directors at its meeting held today, inter alia, considered and approved the Un-Audited Financial Results (Standalone and Consolidated) of the Company for the quarter ended June 30, 2022 prepared in terms of Regulation 33 of the Listing Regulations along with the Limited Review Reports thereon issued by the Statutory Auditors of the Company

The said Un-Audited Financial Results (Standalone and Consolidated) and Limited Review Reports for the said period issued by the Statutory Auditors of the Company are enclosed herewith. The meeting of the Board of Directors commenced at 02:15 PM and concluded at 04:10 PM.

Submitted for your information and records.

Thanking you,

Yours Faithfully,

For Artemis Medicare Services Limited

Shilpa Budhia

(Company Secretary & Compliance Officer)



Independent Auditor's Review Report on unaudited standalone quarterly financial results of Artemis Medicare Services Limited Pursuant to Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015.

To
The Board of Directors
Artemis Medicare Services Limited

1. We have reviewed the accompanying statement of unaudited standalone financial results of **Artemis Medicare Services Limited** ("the Company") for the quarter ended June 30, 2022 (hereinafter referred to as "Statement"), being submitted by the company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended to date ("Listing Regulation").
2. The Statement, which is the responsibility of the Company's Management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34, (Ind AS 34) "Interim Financial Reporting" prescribed under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review in accordance with the *Standard on Review Engagement (SRE) 2410, "Review of Interim Financial Information performed by the Independent Auditor of the Entity"* issued by the Institute of Chartered Accountants of India. This Standard requires that we plan and perform the review to obtain moderate assurance about whether the Statement is free of material misstatement. A review is limited primarily to inquiries of company personnel and an analytical procedure applied to financial data and thus provides less assurance than an audit. We have not performed an audit. Accordingly, we do not express an audit opinion.
4. Based on our review conducted as above, nothing has come to the attention that causes us to believe that the accompanying Statement prepared in all material respects in accordance with applicable accounting standards, and other recognized accounting practices and policies, has not disclosed the information required to be disclosed in terms of Regulation 33 of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For T R Chadha & Co LLP
Chartered Accountants
(Firm Registration No -006711N/ N500028)



Place of Signature: New Delhi
Date: August 11, 2022
UDIN: 22057986AOUQPS8189

Neena Goel
(Partner)
Membership No. 057986

ARTEMIS MEDICARE SERVICES LIMITED

Plot No.14, Sector 20, Dwarka, South West Delhi, Delhi- 110075

Ph.: +91-124-4511111; Fax: +91-124-4588899; Email: info@artemishospitals.com; Website: www.artemishospitals.com

CIN: L85110DL2004PLC126414

STATEMENT OF STANDALONE FINANCIAL RESULTS FOR THE QUARTER ENDED JUNE 30, 2022

(₹ in Lacs)

S No.	Particulars	Quarter ended			Year ended
		30-Jun-22	31-Mar-22	30-Jun-21	31-Mar-22
		(Unaudited)	(Audited) (Refer Note 3)	(Unaudited)	(Audited)
1.	Income				
	(a) Revenue from Operations	16,346.59	14,619.54	12,048.27	54,478.40
	(b) Other Income	226.74	123.67	80.36	388.47
	Total Income	16,573.33	14,743.21	12,128.63	54,866.87
2.	Expenses				
	(a) Operative Expenses	10,322.04	9,126.18	7,479.33	33,537.48
	(b) Purchases of Stock in Trade	0.36	0.17	6.70	9.65
	(c) Changes in inventories of Stock in Trade	(0.36)	3.87	2.49	13.38
	(d) Employee Benefits Expense	2,761.08	2,825.86	2,405.45	10,219.95
	(e) Finance Costs	410.09	350.04	218.78	1,116.61
	(f) Depreciation and Amortization Expense	627.32	608.96	480.58	2,108.20
	(g) Other Expenses	1,335.78	978.28	856.56	3,980.71
	Total Expenses	15,456.31	13,893.36	11,449.89	50,985.98
3.	Profit/(Loss) before exceptional items and tax (1-2)	1,117.02	849.85	678.74	3,880.89
4.	Exceptional Items	-	-	-	-
5.	Profit/(Loss) before tax (3+4)	1,117.02	849.85	678.74	3,880.89
6.	Tax Expense:				
	(a) Current Tax	234.01	(225.65)	291.62	824.52
	(b) Earlier Year Tax	-	(55.13)	-	(55.13)
	(c) Deferred Tax Charge / (Credit)	13.20	(201.57)	(28.59)	(146.24)
	Total Tax Expense	247.21	(482.35)	263.03	623.15
7.	Net Profit/(Loss) after tax for the period/ year (5-6)	869.81	1,332.20	415.71	3,257.74
8.	Other comprehensive income/(loss) for the period/year				
	Items that will not be reclassified to profit or loss				
	(a) Remeasurement of defined employee benefit plans	(29.41)	(113.03)	2.18	(117.64)
	(b) Income Tax relating to items that will not be reclassified to profit or loss	7.40	28.00	(0.76)	29.61
	(c) Deferred Tax adjustment on revaluation that will not be reclassified to profit or loss	13.55	13.56	13.55	54.22
	Net Other comprehensive Income/(loss) for the period/year	(8.46)	(71.47)	14.97	(33.81)
9.	Total comprehensive income/(loss) for the period/ year (7+8)	861.35	1,260.73	430.68	3,223.93
10.	Paid up Equity Share Capital (Face value Re. 1/- each) (Refer Note 4)	1,323.77	1,323.77	1,323.77	1,323.77
11.	Other Equity Excluding Revaluation Reserves	-	-	-	28,144.25
12.	Earning per Equity Share (Face value Re. 1/- each) (Refer Note 4)				
	(a) Basic	0.66*	1.01*	0.31*	2.46
	(b) Diluted	0.63*	0.96*	0.30*	2.34

* Not annualised



Onkar Kaumar

Notes:-

1. The above standalone unaudited financial results for the quarter ended June 30, 2022 have been reviewed by the Audit Committee and subsequently approved by the Board of Directors of the Company at their respective meetings held on August 11, 2022. The statutory auditors have expressed unmodified conclusion on the aforesaid results.

2. The above financial results have been prepared in accordance with the Companies (Indian Accounting Standards) Rules, 2015, as amended (Ind AS), as prescribed under Section 133 of the Companies Act 2013, and the other recognised accounting practices and policies to the extent applicable.

3. The results for the quarter ended March 31, 2022, are the balancing figures between audited figures in respect of full financial year ended March 31, 2022 and published and unaudited results for the nine month period ended December 31, 2021.

4. The Board of Directors of Artemis Medicare Services Limited ('Company') in its meeting held on August 5, 2021, approved a proposal for sub-division of the face value of the equity shares of the Company from Rs. 10 per equity share to Re. 1 per equity share i.e. 1 equity share to be split into 10 equity shares. Subsequent to the approval of the above proposal by the shareholders of the Company, the record date was fixed as September 24, 2021 and thereafter the sub-division became effective. Accordingly, the basic and diluted earnings per equity share (EPS) have been computed for all the periods presented in the Standalone Financial Results of the Company on the basis of new number of equity shares in accordance with Ind AS 33 - Earnings per shares.

5. India's Code on Social Security, 2020, which aims to consolidate, codify and revise certain existing social security laws, received Presidential assent in September 2020 and has been published in the Gazette of India. However, the related final rules have not yet been issued and the date on which this Code will come into effect has not been announced. The Code may impact the contributions by the company towards provident fund, gratuity and ESIC. The Company will assess the impact of this Code and the rules thereunder when they come into effect and will record any related impact, if any, in the period the Code becomes effective.

6. Segment Reporting:Business segment

The Company's operation predominantly comprise of only one business segment of Healthcare Services.

Geographical information

Geographical information analyses the Company's revenue by the country of domicile (i.e. India) and other countries. In presenting the geographical information, segment revenue has been based on the geographical location of the customers.

Region	Revenue from Operations			
	Quarter ended		Year ended	
	30-Jun-22	31-Mar-22	30-Jun-21	31-Mar-22
India	12,373.10	11,222.04	10,164.03	44,952.20
Outside India	3,973.49	3,397.50	1,884.24	9,526.20
Total	16,346.59	14,619.54	12,048.27	54,478.40

Region	Carrying amount of Non-Current Assets			
	Quarter ended		Year ended	
	30-Jun-22	31-Mar-22	30-Jun-21	31-Mar-22
India	58,832.42	56,579.90	49,907.93	56,579.90
Outside India	-	-	-	-
Total	58,832.42	56,579.90	49,907.93	56,579.90

7. During the period ended June 30, 2022, the Company has issued 4.5 lacs number of equity shares (Jun 30, 2021; Nil) each fully paid up at ₹1/- per share to Managing Director pursuant to Artemis Medicare Management Stock Option Plan – 2021 (the Plan), which have been duly listed in the respective Stock Exchanges, ranking pari passu with the existing equity shares of the Company.

8. Previous period's figures have been regrouped / reclassified wherever necessary to correspond with the current period classification / disclosures.



For and on behalf of the Board of Directors
of Artemis Medicare Services Limited

Onkar Kanwar

Onkar Kanwar
Chairman

Place : Gurugram

Dated : August 11, 2022





Independent Auditor's Review Report on unaudited consolidated quarterly financial results of Artemis Medicare Services Limited pursuant to Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015.

**To the Board of Directors of
Artemis Medicare Services Limited**

1. We have reviewed the accompanying Statement of Unaudited Consolidated Financial Results of **Artemis Medicare Services Limited** ("Holding Company") and its subsidiary (the Holding Company and its subsidiary together referred to as "the Group") for the quarter ended June 30, 2022, ("Consolidated Statement"), being submitted by the Holding Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("Listing regulation").
2. This Consolidated Statement, which is the responsibility of the Holding Company's Management and approved by the Holding Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34, (Ind AS 34) "Interim Financial Reporting" prescribed under Section 133 of the Companies Act, 2013, read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Consolidated Statement based on our review.
3. We conducted our review of the Consolidated Statement in accordance with the *Standard on Review Engagements (SRE) 2410 'Review of Interim Financial Information Performed by the Independent Auditor of the Entity'*, issued by the Institute of Chartered Accountants of India (ICAI). This Standard requires that we plan and perform the review to obtain moderate assurance as to whether the Consolidated Statement is free of material misstatement. A review of interim financial information consists of making inquiries, primarily of the Company's personnel responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under section 143(10) of the Companies Act, 2013 and consequently, does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

We also performed procedures in accordance with the circulars issued by the SEBI under Regulations 33(8) of the SEBI (Listing Obligations and Disclosure Requirement) Regulations, 2018 as amended, to the extent applicable.

4. The Statement includes the results of the Holding Company and the Subsidiary Company i.e. **Artemis Cardiac Care Private Limited**.
5. Based on our review conducted and procedures performed as stated in paragraph 3 above, nothing has come to our attention that causes us to believe that the accompanying Consolidated Statement, prepared in all material respects in accordance with applicable Indian Accounting Standards prescribed under Section 133 of the Companies Act, 2013, and other recognized accounting practices and policies, has not disclosed the information required to be disclosed in terms of the Listing Regulation including the manner in which it is to be disclosed, or that it contains any material misstatement.



T R Chadha & Co., a partnership firm converted into T R Chadha & Co LLP
(A limited liability partnership with LLP Identification No. AAF-3926) with effect from 28th December, 2015

Other Matters

6. We did not review the interim standalone financial information of the subsidiary company viz Artemis Cardiac Care Private Limited, whose interim financial information reflect a total revenue of ₹ 376.72 lakhs, total comprehensive loss of ₹ (43.12) lakhs (comprising of net loss of ₹ (43.21) lakhs and Other comprehensive income of ₹ 0.09 lakhs) for the quarter ended on June 30, 2022, as considered in the Consolidated Statement. These interim financial statements and other financial information have been reviewed by another firm of Chartered accountants whose review reports, vide which they have issued an unmodified conclusion, have been furnished to us by the Management and our conclusion on the Consolidated Statement, in so far as it relates to the amounts and disclosures included in respect of the subsidiary company, is based solely on the report of such other auditors and the procedures performed by us as stated in paragraph 3 above.
7. Attention is drawn to the fact that the figures for the three months ended March 31, 2022, as reported in the Consolidated Statement are the balancing figures between audited figures in respect of the full previous financial year and the published year-to-date figures up to the third quarter of the previous financial year. The figures up to the end of the third quarter of the previous financial year had only been reviewed and not subjected to audit.

Our conclusion on the Consolidated Statement is not modified in respect of these matters.

For T R Chadha & Co LLP
Chartered Accountants
(Firm Registration No -006711N/ N500028)



Place of Signature: New Delhi
Date: August 11, 2022
UDIN: 22057986AOURBH6808

Neena Goel
(Partner)
Membership No. 057986

ARTEMIS MEDICARE SERVICES LIMITED

Plot No.14, Sector 20, Dwarka, South West Delhi, Delhi- 110075

Ph.: +91-124-4511111; Fax: +91-124-4588899; Email: info@artemishospitals.com; Website: www.artemishospitals.com

CIN: L85110DL2004PLC126414

STATEMENT OF CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER ENDED JUNE 30, 2022

(₹ in Lacs)

S No.	Particulars	Quarter ended			Year ended
		30-Jun-22	31-Mar-22	30-Jun-21	31-Mar-22
		(Unaudited)	(Audited) (Refer Note 4)	(Unaudited)	(Audited)
1.	Income				
	(a) Revenue from Operations	16,723.32	14,943.20	12,228.50	55,480.12
	(b) Other Income	230.70	123.86	80.47	389.94
	Total Income	16,954.02	15,067.06	12,308.97	55,870.06
2.	Expenses				
	(a) Operative Expenses	10,578.91	9,321.51	7,589.89	34,154.40
	(b) Purchases of Stock in Trade	0.36	0.17	6.70	9.65
	(c) Changes in inventories of Stock in Trade	(0.36)	3.87	2.49	13.38
	(d) Employee Benefits Expense	2,835.28	2,889.88	2,451.59	10,430.00
	(e) Finance Costs	432.29	370.78	238.50	1,197.51
	(f) Depreciation and Amortization Expense	659.26	639.32	506.94	2,219.28
	(g) Other Expenses	1,387.04	1,022.09	877.51	4,127.36
	Total Expenses	15,892.78	14,247.62	11,673.62	52,151.58
3.	Profit/(Loss) before exceptional items and tax (1-2)	1,061.24	819.44	635.35	3,718.48
4.	Exceptional Items	-	-	-	-
5.	Profit/(Loss) before tax (3+4)	1,061.24	819.44	635.35	3,718.48
6.	Tax Expense:				
	(a) Current Tax	234.01	(225.65)	291.62	824.52
	(b) Earlier Year Tax	-	(55.13)	-	(55.13)
	(c) Deferred Tax Charge / (Credit)	0.62	(220.44)	(30.03)	(191.06)
	Total Tax Expense	234.63	(501.22)	261.59	578.33
7.	Net Profit/(Loss) after tax for the period/ year (5-6)	826.61	1,320.66	373.76	3,140.15
8.	Other comprehensive income/(loss) for the period/year				
	Items that will not be reclassified to profit or loss				
	(a) Remeasurement of defined employee benefit plans	(29.29)	(113.21)	2.41	(117.16)
	(b) Income Tax relating to items that will not be reclassified to profit or loss	7.37	28.04	(0.82)	29.47
	(c) Deferred Tax adjustment on revaluation that will not be reclassified to profit or loss	13.55	13.56	13.55	54.22
	Net Other comprehensive income/(loss) for the period/year	(8.37)	(71.61)	15.14	(33.47)
9.	Total comprehensive income/(loss) for the period/ year (7+8)	818.24	1,249.05	388.90	3,106.68
10.	Profit/(Loss) for the period attributable to :				
	Shareholders of the Company	841.74	1,324.73	388.48	3,181.44
	Non-Controlling Interest	(15.13)	(4.07)	(14.72)	(41.29)
11.	Total Comprehensive Income / (Loss) for the period attributable to :				
	Shareholders of the Company	833.34	1,253.17	403.55	3,147.84
	Non-Controlling Interest	(15.10)	(4.12)	(14.66)	(41.16)
12.	Paid up Equity Share Capital (Face value Re. 1/- each) (Refer Note 6)	1,323.77	1,323.77	1,323.77	1,323.77
13.	Other Equity Excluding Revaluation Reserves	-	-	-	27,925.53
14.	Earning per Equity Share (Face value Re. 1/- each) (Refer Note 6)				
	(a) Basic	0.64*	1.00*	0.29*	2.40
	(b) Diluted	0.61*	0.95*	0.28*	2.29

* Not annualised



Onkar Kumar

Notes:-

1. The above consolidated unaudited financial results for the quarter ended June 30, 2022 have been reviewed by the Audit Committee and subsequently approved by the Board of Directors of the Company at their respective meetings held on August 11, 2022. The statutory auditors have expressed unmodified conclusion on the aforesaid results.
2. The consolidated unaudited financial results includes the results of the Company and one subsidiary. The Company together with its subsidiary is herein referred to as the Group.
3. The above consolidated financial results have been prepared in accordance with the Companies (Indian Accounting Standards) Rules, 2015, as amended (Ind AS), as prescribed under Section 133 of the Companies Act 2013, and the other recognised accounting practices and policies to the extent applicable.
4. The results for the quarter ended March 31, 2022, are the balancing figures between audited figures in respect of full financial year ended March 31, 2022 and published and unaudited results for the nine month period ended December 31, 2021.
5. India's Code on Social Security, 2020, which aims to consolidate, codify and revise certain existing social security laws, received Presidential assent in September 2020 and has been published in the Gazette of India. However, the related final rules have not yet been issued and the date on which this Code will come into effect has not been announced. The Code may impact the contributions by the Group towards provident fund, gratuity and ESIC. The Group will assess the impact of this Code and the rules thereunder when they come into effect and will record any related impact, if any, in the period the Code becomes effective.
6. The Board of Directors of Artemis Medicare Services Limited ('Group') in its meeting held on August 5, 2021, approved a proposal for sub-division of the face value of the equity shares of the Company from Rs. 10 per equity share to Re. 1 per equity share i.e. 1 equity share to be split into 10 equity shares. Subsequent to the approval of the above proposal by the shareholders of the Company, the record date was fixed as September 24, 2021 and thereafter the sub-division became effective. Accordingly, the basic and diluted earnings per equity share (EPS) have been computed for all the periods presented in the Consolidated Financial Results of the Group on the basis of new number of equity shares in accordance with Ind AS 33 - Earnings per shares.

7. Segment Reporting at Consolidated level**Business segment**

The Group's operation predominantly comprise of only one business segment of Healthcare Services.

Geographical information

Geographical information analyses the Group's revenue by the Group's country of domicile (i.e. India) and other countries. In presenting the geographical information, segment revenue has been based on the geographical location of the customers.

Region	Revenue from Operations			
	Quarter ended			Year ended
	30-Jun-22	31-Mar-22	30-Jun-21	31-Mar-21
India	12,749.83	11,545.70	10,344.26	45,953.92
Outside India	3,973.49	3,397.50	1,884.24	9,526.20
Total	16,723.32	14,943.20	12,228.50	55,480.12

Region	Carrying amount of Non-Current Assets			
	Quarter ended			Year ended
	30-Jun-22	31-Mar-22	30-Jun-21	31-Mar-21
India	60,168.15	57,923.02	51,058.28	57,923.02
Outside India	-	-	-	-
Total	60,168.15	57,923.02	51,058.28	57,923.02

8. During the period ended June 30, 2022, the Group has issued 4.5 lacs number of equity shares (Jun 30, 2021; Nil) each fully paid up at ₹1/- per share to Managing Director pursuant to Artemis Medicare Management Stock Option Plan – 2021 (the Plan), which have been duly listed in the respective Stock Exchanges, ranking pari passu with the existing equity shares of the Company.

9. Previous period's figures have been regrouped / reclassified wherever necessary to correspond with the current period classification / disclosures.



For and on behalf of the Board of Directors
of Artemis Medicare Services Limited

Onkar Kanwar

Onkar Kanwar
Chairman

Place : Gurugram

Dated : August 11, 2022

